Close Menu

No Dice

The Wall Street Journal's Deal Book wonders why there are so few deals going on in Europe's biopharma arena -- $137 billion of health-care deals have gone down so far this year in the US. It's not for lack of trying. "One potential deal after another has fallen apart," the article says, citing companies such as Nycomed, Crucell, and Actavis that have explored sales only to have them fall through.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.